CoChat

Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism

Open access

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide 1 (GLP-1) increases tissue glucose uptake and causes vasodilation independent of insulin. We examined the effect of GLP-1 on muscle microvasculature and glucose uptake. After confirming that GLP-1 potently stimulates nitric oxide (NO) synthase (NOS) phosphorylation in endothelial cells, overnight-fasted adult male rats received continuous GLP-1 infusion (30 pmol/kg/min) for 2 h plus or minus NOS inhibition. Muscle microvascular blood volume (MBV), microvascular blood flow velocity (MFV), and microvascular blood flow (MBF) were determined. Additional rats received GLP-1 or saline for 30 min and muscle insulin clearance/uptake was determined. GLP-1 infusion acutely increased muscle MBV (P < 0.04) within 30 min without altering MFV or femoral blood flow. This effect persisted throughout the 120-min infusion period, leading to a greater than twofold increase in muscle MBF (P < 0.02). These changes were paralleled with increases in plasma NO levels, muscle interstitial oxygen saturation, hind leg glucose extraction, and muscle insulin clearance/uptake. NOS inhibition blocked GLP-1–mediated increases in muscle MBV, glucose disposal, NO production, and muscle insulin clearance/uptake. In conclusion, GLP-1 acutely recruits microvasculature and increases basal glucose uptake in muscle via a NO-dependent mechanism. Thus, GLP-1 may afford potential to improve muscle insulin action by expanding microvascular endothelial surface area.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db11-1073

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Animal study protocols.
FIG. 1. Animal study protocols.CC BY-NC-ND · PubMed Central
FIG. 2. Effects of GLP-1 on Akt, eNOS, and PKA in cultured ECs. Representative gels and quantifications of Akt (Ser473) (A), eNOS (Ser1177) (B and C), eNOS (Ser635) (D), and PKA (E) phosphorylation. n = 4–9 each. Compared with basal, *P < 0.05, **P < 0.01. Insulin (100 nmol/L) was used as positive control.
FIG. 2. Effects of GLP-1 on Akt, eNOS, and PKA in cultured ECs. Representative gels and quantifications of Akt (Ser473) (A), eNOS (Ser1177) (B and C), eNOS (Ser635) (D), and PKA (E) phosphorylation. n = 4–9 each. Compared with basal, *P < 0.05, **P < 0.01. Insulin (100 nmol/L) was used as positive control.CC BY-NC-ND · PubMed Central
FIG. 3. Effects of GLP-1 on muscle microvascular recruitment. GLP-1 was infused continuously at 30 pmol/kg/min in the absence or presence of l-NAME, which was infused systemically starting 30 min before the initiation of GLP-1 infusion. A: Changes in MBV. B: Changes in MFV. C: Changes in MBF. Compared with 0 min, *P < 0.05, #P < 0.01. n = 4–8 each.
FIG. 3. Effects of GLP-1 on muscle microvascular recruitment. GLP-1 was infused continuously at 30 pmol/kg/min in the absence or presence of l-NAME, which was infused systemically starting 30 min before the initiation of GLP-1 infusion. A: Changes in MBV. B: Changes in MFV. C: Changes in MBF. Compared with 0 min, *P < 0.05, #P < 0.01. n = 4–8 each.CC BY-NC-ND · PubMed Central
FIG. 4. Effects of GLP-1 on plasma NO and insulin levels, muscle oxygenation, and eNOS phosphorylation. GLP-1 was infused continuously at 30 pmol/kg/min. A: Changes in plasma NO levels during GLP-1 infusion. #P < 0.01 vs. 0 min; P < 0.04 between the two groups (ANOVA). B: Changes in plasma NO levels during l-NAME + GLP-1 infusion. Compared with −30 min, #P < 0.01. C: Changes in muscle eNOS (Ser1177) phosphorylation. P = 0.8. D: Changes in muscle oxygen saturation over time. #P < 0.05 vs. 0 min; P < 0.02 between the two groups (ANOVA). E: Plasma insulin concentrations. P = 0.437 (ANOVA). F: Arterial glucose concentrations. *P < 0.01 vs. 0 min. n = 5–9 each.
FIG. 4. Effects of GLP-1 on plasma NO and insulin levels, muscle oxygenation, and eNOS phosphorylation. GLP-1 was infused continuously at 30 pmol/kg/min. A: Changes in plasma NO levels during GLP-1 infusion. #P < 0.01 vs. 0 min; P < 0.04 between the two groups (ANOVA). B: Changes in plasma NO levels during l-NAME + GLP-1 infusion. Compared with −30 min, #P < 0.01. C: Changes in muscle eNOS (Ser1177) phosphorylation. P = 0.8. D: Changes in muscle oxygen saturation over time. #P < 0.05 vs. 0 min; P < 0.02 between the two groups (ANOVA). E: Plasma insulin concentrations. P = 0.437 (ANOVA). F: Arterial glucose concentrations. *P < 0.01 vs. 0 min. n = 5–9 each.CC BY-NC-ND · PubMed Central
FIG. 5. Effects of GLP-1 on muscle glucose extraction. A: Saline control. P > 0.05 (ANOVA); n = 5. B: GLP-1 group. Compared with basal, *P < 0.05, n = 6; P = 0.008 (ANOVA). C: l-NAME + GLP-1 group. P > 0.05 (ANOVA); n = 5. GLP-1 was infused continuously at 30 pmol/kg/min. l-NAME was infused systemically starting 30 min before the initiation of GLP-1 infusion.
FIG. 5. Effects of GLP-1 on muscle glucose extraction. A: Saline control. P > 0.05 (ANOVA); n = 5. B: GLP-1 group. Compared with basal, *P < 0.05, n = 6; P = 0.008 (ANOVA). C: l-NAME + GLP-1 group. P > 0.05 (ANOVA); n = 5. GLP-1 was infused continuously at 30 pmol/kg/min. l-NAME was infused systemically starting 30 min before the initiation of GLP-1 infusion.CC BY-NC-ND · PubMed Central
FIG. 6. Effects of GLP-1 on muscle insulin clearance and uptake. A: Fraction of intact 125I-insulin in blood and muscle; blood (white bar), muscle (gray bar). Compared with blood, #P < 0.01. B: Muscle 125I-insulin clearance. Compared with saline, *P = 0.02 (ANOVA). C: Muscle 125I-insulin uptake. Compared with saline, #P < 0.01 (ANOVA). n = 5–9 each.
FIG. 6. Effects of GLP-1 on muscle insulin clearance and uptake. A: Fraction of intact 125I-insulin in blood and muscle; blood (white bar), muscle (gray bar). Compared with blood, #P < 0.01. B: Muscle 125I-insulin clearance. Compared with saline, *P = 0.02 (ANOVA). C: Muscle 125I-insulin uptake. Compared with saline, #P < 0.01 (ANOVA). n = 5–9 each.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 201

Metadata

Authors
Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z.
Affiliations
  • University of Virginia Health System (US)
  • Shandong University (CN)
  • Central South University (CN)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Liu, Zhenqi
Venue
Diabetes
Published
2012-03-14
Volume
61
Issue
4
Pages
888-896
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2130375560
Cited by
194
References
47
Citations by year
2026: 10 · 2025: 10 · 2024: 9 · 2023: 9 · 2022: 11 · 2021: 17 · 2020: 13 · 2019: 9 · 2018: 17 · 2017: 8 · 2016: 13 · 2015: 15 · 2014: 24 · 2013: 23 · 2012: 6
FWCI
17.45
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association (1-11-CR-30, 9-09-NOVO-11)
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (R01HL094722)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
glucagon-like peptide-1, nitric oxide, nitric oxide synthase, muscle microvasculature, muscle glucose uptake, microvascular blood flow, endothelial cells, insulin clearance, insulin resistance, vasodilation, glucose extraction
MeSH terms
Animals, Aorta, Cattle, Cells, Cultured, Drug Administration Schedule, Gene Expression Regulation, Glucose, Hormones, Insulin, Male, Nitric Oxide, Somatostatin, Rats, Sprague-Dawley, Cyclic AMP-Dependent Protein Kinases, Muscle, Skeletal, NG-Nitroarginine Methyl Ester, Endothelial Cells, Proto-Oncogene Proteins c-akt, Rats, Glucagon-Like Peptide 1, Nitric Oxide Synthase Type III, Microvessels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.